PresseBox
Pressemitteilung BoxID: 784269 (Biocartis NV)
  • Biocartis NV
  • Generaal de Wittelaan 11 B3
  • 2800 Mechelen
  • http://www.biocartis.com
  • Ansprechpartner
  • Renate Degrave
  • +32 (15) 631-729

Biocartis to host webcast to announce its 2015 financial results on 17 March 2016

(PresseBox) (Mechelen, Belgium, ) Biocartis Group NV (the 'Company' or 'Biocartis'), an innovative molecular diagnostics company, today announces that it will host a live webcast on Thursday, 17 March 2016 at 14:00h CET to announce its 2015 results, 2016 outlook and update on its menu of Idylla(TM) molecular diagnostic tests.

The live webcast may be accessed on the Biocartis website or by clicking here. To participate in the questions and answers session, please dial in 5-10 minutes prior to the start time using the numbers below, followed by the confirmation code 1026764. The webcast and conference call will be conducted in English. A replay of the webcast will be available on the Biocartis website ('investors') shortly after.

Conference call dial-ins:


London, United Kingdom (standard international): +44(0)20 3427 1914
Brussels, Belgium: +32(0)2 404 0662
Amsterdam, Netherlands: +31(0)20 716 8296
New York, USA: +1646 254 3388
Paris, France: +33(0)1 76 77 22 25


Confirmation code: 1026764

Biocartis NV

Biocartis (Euronext Brussels: BCART) is an innovative molecular diagnostics (MDx) company providing next generation diagnostic solutions aimed at improving clinical practice for the benefit of patients, clinicians, payers and industry. Biocartis' proprietary MDx Idylla(TM) platform is a fully automated sample-to-result, real-time PCR (Polymerase Chain Reaction) system that offers accurate, highly reliable molecular information from virtually any biological sample in virtually any setting. Idylla(TM) addresses the growing demand for personalized medicine by allowing fast and effective treatment selection and treatment progress monitoring.

Biocartis launched the Idylla(TM) platform in September 2014. Biocartis is developing and marketing a rapidly expanding test menu addressing key unmet clinical needs in oncology and infectious diseases. These areas represent respectively the fastest growing and largest segments of the MDx market worldwide.

More information: www.biocartis.com